Wednesday, 01 February 2012 10:50

Cytori- The Basic science of ADRCs

The basic science of Cytori- Properties of ADRC´s versus other cell sources

This comes straight from the Cytori homepage:

Science & Technology

Cytori Therapeutics’ goal is to provide access to clinical grade Adipose-Derived Stem and Regenerative Cells (ADRCs). ADRCs, sometimes referred to as stromal vascular fraction cells, are a heterogeneous or mixed population of cells found in adipose tissue. This population includes adult stem cells, endothelial progenitor cells, leukocytes, endothelial cells, and vascular smooth muscle cells. Autologous adult stem and regenerative cells are thought to promote healing of scarred or injured tissue.

While we are learning more about the exact mechanisms every day, it is believed that this heterogeneous population of cells influences the local environment via cell-to-cell signaling, immune modulation, and differentiation into other cell types.

The use of ADRCs in the treatment of many different medical conditions (including cardiovascular disease, soft tissue defects, wound healing, and many more) is being evaluated in numerous clinical and preclinical studies around the world.

The use of ADRCs is a unique and promising approach and holds key advantages over stem and regenerative cells from other sources. While stem and progenitor cells usually make up less than 5% of all ADRCs, this is 2,500-fold more than the frequency of such cells in tissues such as bone marrow (0.002%). The abundance of ADRCs in adipose tissue and the ability to easily collect large amounts of adipose tissue via liposuction eliminates the need for tissue culturing.


ADRC´s hold key advantages over stem and regenerative cells from other sources.

This is the key statement. Every investor who isnt a molecular biologist has to wrestle through expert- and "lesser expert" explanations of financial analysts nowadays, who try to explain, over and over again, the differences in sources of cells and their ASSUMED potency and risks, when they discuss a company in the stem cell space. Most Cytori investors are now well acquainted with fancy words like pluripotency, multipotency etc. What key to know is, is that we at present composition-cells-adipose-tissuestill only see the top of the iceberg of the potential of ADRC´s. It has been 40 years that marrow cells have been studied and characterized. Caplan added the Mesenchymal stem cell to his and the scientific communities general knowledge about 20 years ago, but only since 5-10 years the scientific research has truly commenced in respect of ADRC´s. We are going from, yes they look like BMRC´s to -yes- they seem to have more potent cell types and are much easier accessable etc etc. On my page on adult stemcells all aspects of the technology of adult stem cells is explained in detail- so refer to that info please, if required. Here just the picture of the cell types included in fat and some slides from Eric Duckers- Erasmus on the theme.


The ideal cell and more

duckers1 duckers2

So what these slides are basically saying- ideal are the MSCs, which can come from different tissue types, but you can get more-, better manipulable-and faster those preferred MSCs from adipose tissue compared to all other known sources.


duckers3 duckers4

Here the advantage in respect of ADRCs are quantified on the left and of course one can catch up on the quantitive issue by culturing, which has its distinct risks and disadvantages as stated on the right slide.

Personally I consider the "size" issue as extremely relevant since the cells, the bigger they get, the more prone they are to get squeezed (cell lysis) in a needle by the sheer force of injection. Thereto "the smaller the better", which applies to all cells that have to pass a human membrane like the blood-brain barrier.

Last modified on Monday, 22 February 2016 05:08

Comments (0)

There are no comments posted here yet

Leave your comments

  1. Posting comment as a guest. Sign up or login to your account.
Attachments (0 / 3)
Share Your Location

Copyright Information

Copyright Fas Kuiters © 2016 All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.



Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites